Clinical significance of allelotype profiling for urothelial carcinoma.
OBJECTIVE
To perform a global loss of heterozygosity (LOH) analysis on a cohort of urothelial carcinoma to investigate the clinical implication of specific chromosomal loss. Allelic deletions detected as LOH have been used to study the markers for carcinogenesis.


METHODS
We examined the allelic loss on 14 chromosomal regions in a total of 71 cases of urothelial carcinoma. The results were analyzed in relation to biologic indicators of urothelial carcinoma and the clinical outcome with a mean follow-up of 101 months.


RESULTS
The incidence of LOH in order of frequency was 9p (54.9%), 9q (49.3%), 13q (40.8%), 14q (40.8%), 10q (39.4%), 17p (39.4%), 8p (38.0%), 21q (36.6%), 11p (31.0%), 18q (23.9%), 4q (21.1%), 3p (16.9%), 6q (14.1%), and 1q (8.5%). Positive association with one of the indicators was observed in 3p, 9p, 9q, 10q, 14q, and 18q. The chromosomes that correlated with two biologic indicators were 4q, 6q, 11p, 17p, and 21q. Univariate analysis found that patients having combined 9p and 14q deleted tumors had particularly poor long-term survival compared with those with other patterns of chromosomal alterations (P = 0.01). In the multivariate model, nonpapillary tumors had a greater risk of recurrence, and stage classification was the only important indicator in predicting patient survival (P = 0.04).


CONCLUSIONS
LOH assessment does not provide independent prognostic value compared with stage classification. However, chromosomes 4q, 6q, 9p, 11p, 14q, 17p, and 21q may harbor important tumor suppressor genes involved in the progression of urothelial carcinogenesis.
Tzai
Tzong-Shin
TS
Department of Urology, National Cheng Kung University Hospital, Tainan, Taiwan.
Chen
Helen Hai-Wen
HH
Chan
Shih-Huang
SH
Ho
Chung-Liang
CL
Tsai
Yuh-Shyan
YS
Cheng
Hong-Lin
HL
Dai
Yuan-Chang
YC
Lin
Johnny Shinn-Nan
JS
Yang
Wen-Hong
WH
Chow
Nan-Haw
NH
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000483:Alleles; D002295:Carcinoma, Transitional Cell / Q000235:genetics* / Q000473:pathology; D002872:Chromosome Deletion; D002874:Chromosome Mapping; D015331:Cohort Studies; D005260:Female; D020869:Gene Expression Profiling / Q000379:methods*; D005838:Genotype; D006801:Humans; D007680:Kidney Neoplasms / Q000235:genetics / Q000473:pathology; D019656:Loss of Heterozygosity / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D014516:Ureteral Neoplasms / Q000235:genetics / Q000473:pathology; D001749:Urinary Bladder Neoplasms / Q000235:genetics* / Q000473:pathology